

### Patent Claims

1. Use of *Hypericum perforatum* (St John's wart) and/or *Ginkgo biloba* (ginkgo) and/or *Crocus sativus* (saffron) and/or *Panax ginseng* (ginseng) for the treatment of schizophrenia.
2. Use according to claim 1, wherein the plant, plant parts, dried plant or plant parts, extracts, extract fractions, pure substances and their derivatives and the salts of the plant are used.
3. Use according to one of the preceding claims, wherein the extract used is an alcoholic, alcoholic-aqueous extract with primary, secondary and tertiary alcohols of the series C1 to C5, preferably methanol and ethanol, in the composition of alcohol/water of between 100/0 to 30/70, preferably 80/20 to 50/50.
4. Use according to claim 3, wherein these are produced in a one- and multi-step production process.
5. Use according to one of claims 1 to 4, wherein the St John's wart extract used has the following amounts of components: 0.01 – 2% hypericins, 0.01 – 30% hyperforins, 2 – 35% flavonoids, preferably 0.10 to 0.40% hypericins and 1 – 6% hyperforins.
6. Use according to one of claims 1 to 4, wherein the ginkgo extract has the following amounts and components: 20 to 30% by weight flavone glycosides, together with 2 – 8% by weight of ginkgolides, particularly preferred 23 to 27% flavone glycosides and 5 to 7% by weight ginkgolides.
7. Use according to one of claims 1 to 4, wherein the saffron extract comprises the components  $\alpha$ -,  $\beta$ -pinene, 1,8 cineol, crocin, picrocrocin as well as optionally the degradation product thereof safranal, particularly preferred in the following concentrations: 5 – 10% pinene and cineol, 4 – 10% picrocrocin and/or 2 – 6% safranal.
8. Use according to one of claims 1 to 4, wherein the ginseng root extract comprises the components, *inter alia*, triterpene saponines (ginsenosides/ginsenoids), sesquiterpenes and polyacetylenes, particularly preferred in the following concentrations: 3 – 9% ginsenoids.

9. Use according to one of the preceding claims, wherein use occurs in the form of liquid, semi-solid and solid forms of administration, in particular solutions, suspensions, tablets, film-coated tablets, dragees, capsules, effervescent tablets, effervescent granulate, chew tablets and suppositories.
10. Use according to one of the preceding claims, wherein in the case of St John's wart extract, the daily dose of the extracts is 300 to 2700 mg in up to 3 separate doses per day, preferably 750 – 1500 mg in 1 – 2 separate doses per day.
11. Use according to one of the preceding claims, wherein in the case of *Ginkgo biloba*, *Crocus sativus* and *Panax ginseng*, the daily dose of the extracts is 50 mg – 1000 mg of extract.
12. Combination preparation containing St John's wart, ginkgo, saffron and/or ginseng in addition to, as a further component, a psychotherapeutic drug against schizophrenia for the simultaneous, separate or graduated use in the treatment of schizophrenia.
13. Use according to one of claims 1 to 11 in add-on therapy in combination with psychotherapeutic drugs for treating schizophrenia, in particular neuroleptics, in particular of the group of classic neuroleptics such as haloperidol, benperidol, chlorprotixene, flupentixol, fluphenazine, perazine, perphenazine, thioridazine, atypical neuroleptics, in particular clozapine, olanzapine, seroquel, sertindole, as well as other psychotherapeutic drugs suitable for treating schizophrenia.
14. Method for the treatment of schizophrenia, comprising the administration of *Hypericum perforatum* (St John's wart) and/or *Ginkgo biloba* (ginkgo) and/or *Crocus sativus* (saffron) and/or *Panax ginseng* (ginseng) to individuals suffering from schizophrenia.
15. Method according to claim 14, wherein the plant, plant parts, dried plant or plant parts, extracts, extract fractions, pure substances and their derivatives and the salts of the plant are administered to the individual for the treatment of schizophrenia.
16. Method according to claim 14 or 15, wherein the extract is one of those cited in claims 3 to 8.
17. Method according to one of claims 14 to 16, comprising the further simultaneous, separate or graduated administration of the aforementioned active substances with a

conventional psychotherapeutic drug against schizophrenia for the treatment of schizophrenia.